High-intensity focused ultrasound for prostate cancer

Napoli, Alessandro; Alfieri, Giulia; Scipione, Roberto; Leonardi, Andrea; Fierro, Davide; Panebianco, Valeria; Nunzio, Cosimo De; Leonardo, Costantino; Catalano, Carlo

doi:10.1080/17434440.2020.1755258

Cited by 42 publications

(25 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the unprecedented potential of high intensity focused ultrasound (HIFU) for cancer therapy, to achieve precise HIFU ablation has remained a challenge. [1][2][3] HIFU destroys the tumor tissue by focusing the ultrasound from an in vitro transducer into tumor tissue to generate a high temperature within a few seconds and then induces obvious thermal coagulation necrosis. 4 Unfortunately, the efficacy of HIFU ablation is low when the focused ultrasound reaches the deep-seated organs due to the attenuation of ultrasound energy along the ultrasound pathway, which often needs higher ultrasound power and longer ablation duration.…”

Section: Introductionmentioning

confidence: 99%

Bifidobacterium bifidum-Mediated Specific Delivery of Nanoparticles for Tumor Therapy

Tang¹,

Chen²,

Jiang³

et al. 2021

IJN

View full text Add to dashboard Cite

Purpose: Hypoxia is considered to be obstructive to tumor treatment, but the reduced oxygen surroundings provide a suitable habitat for Bifidobacterium bifidum (BF) to colonize. The anaerobe BF selectively colonizes into tumors following systemic injection due to its preference for the hypoxia in the tumor cores. Therefore, BF may be a potential targeting agent which could be used effectively in tumor treatment. We aimed to determine whether a novel BF-mediated strategy, that was designed to deliver AP-PFH/PLGA NPs (aptamers CCFM641-5-functionalized Perfluorohexane (PFH) loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles) by aptamer-directed approach into solid tumor based on the tumortargeting ability of BF, could improve efficiency of high intensity focused ultrasound (HIFU) treatment of breast cancer. Methods: We synthesized AP-PFH/PLGA NPs using double emulsion method and carbodiimide method. Then, we evaluated targeting ability of AP-PFH/PLGA NPs to BF in vivo. Finally, we studied the efficacy of HIFU ablation based on BF plus AP-PFH/PLGA NPs (BFmediated HIFU ablation) in tumor. Results: The elaborately designed AP-PFH/PLGA NPs can target BF colonized in tumor to achieve high tumor accumulation, which can significantly enhance HIFU therapeutic efficiency. We also found that, compared with traditional chemotherapy, this therapy not only inhibits tumor growth, but also significantly prolongs the survival time of mice. More importantly, this treatment strategy has no obvious side effects. Conclusion:We successfully established a novel therapy method, BF-mediated HIFU ablation, which provides an excellent platform for highly efficient and non-invasive therapy of tumor.

show abstract

Section: Introductionmentioning

confidence: 99%

Bifidobacterium bifidum-Mediated Specific Delivery of Nanoparticles for Tumor Therapy

Tang¹,

Chen²,

Jiang³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…Besides oncological criteria, the size of the prostate gland also determines the outcome of treatment. The transrectal route of energy delivery by the HIFU probe may hinder access to anterior lesion [ 10 ], and the tissue swelling after HIFU treatment renders the placement of a urethral or suprapubic catheter, a common practice after the procedure [ 11 ]. Such change in prostate size has led to some centres performing transurethral resection of prostate (TURP) before or simultaneously with the HIFU procedure [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform

Yee

Chiu

Teoh

et al. 2021

Advances in Urology

View full text Add to dashboard Cite

Objective. The study aimed at investigating the outcome of prostate HIFU focal therapy using the MRI-US fusion platform for treatment localization and delivery. Methods. It is a prospectively designed case series of HIFU focal therapy for localized prostate cancer. The inclusion criteria include clinical tumor stage ≤T2, visible index lesion on multiparametric MRI less than 20 mm in diameter, absence of Gleason 5 pattern on prostate biopsy, and PSA ≤ 20 ng/ml. HIFU focal therapy was performed in the conventional manner in the beginning 50% of the series, whereas the subsequent cases were performed with MRI-US fusion platform. The primary outcome was treatment failure rate which is defined by the need of salvage therapy. Secondary outcomes included tumor recurrence in follow-up biopsy, PSA change, perioperative complications, and postoperative functional outcomes. Results. Twenty patients underwent HIFU focal ablation. HIFU on an MRI-US fusion platform had a trend of a longer total operative time than the conventional counterpart (124.2 min vs. 107.1 min, p = 0.066 ). There was no difference in the mean ablation volume to lesion volume ratio between the two. The mean PSA percentage change from baseline to 6-month is more significant in the conventional group (63.3% vs. 44.6%, p = 0.035 ). No suspicious lesion was seen at 6-month mpMRI in all 20 patients. Two patients, one from each group, eventually underwent radical treatment because of the presence of clinically significant prostate cancer in the form of out-of-field recurrences during follow-up biopsy. No significant difference was observed before and after HIFU concerning uroflowmetry, SF-12 score, and EPIC-26 score. It was observed that energy used per volume was positively correlated with PSA density of the patient (r = 0.6364, p = 0.014 ). Conclusion. In conclusion, HIFU with conventional or MRI-US fusion platform provided similar oncological and functional outcomes.

show abstract

“…An IDE application contains the following: (1) name and address of sponsor, (2) a report of prior investigation of the device, (3) an investigational plan, (4) a description of manufacture, processing, packing, storage, etc. of the device, (5) the agreement to be signed by investigators prior to their participation and a list of all investigators, (6) certification that all investigators will have signed the agreement prior to participating in the study, (7) information regarding all IRBs that have been or will be asked to review the protocol, (8) information regarding institutions where the investigation may be conducted, ( 9) amount (if any) charged for the device and an explanation of why sale does not constitute commercialization, (10) information regarding an environmental assessment, (11) device labeling information, (12) all informed consent materials and related information to be provided to subjects, and (13) any additional relevant information that the FDA requests in order to perform a complete review. Detailed requirements for the contents of the IDE application can be found in 21 CFR 812.20.…”

Section: Investigational Device (Ide) Applicationsmentioning

confidence: 99%

“…While therapeutic ultrasound is not a new technology, with its use first being reported over 70 years ago, [3][4][5] it was not until coupling the technology with MRI, 6,7 to provide non-invasive monitoring of treatments and design and production of clinical body systems that regulatory approval was obtained in 2004 from the U.S. Food and Drug Administration (FDA), initially for the thermal ablation treatment of uterine fibroids by a commercial system. 8 Further technological advances have led to the development of specialized MRgFUS system configurations, such as brain, 9 prostate, 10 breast, 11,12 topical applicators, [13][14][15] and interstitial probes. 16,17 Subsequently, FDA approvals and clearances have been issued for other oncologic and neurologic indications including essential tremor, bone metastases, and prostate tissue.…”

Section: Introductionmentioning

confidence: 99%

AAPM Task Group 241: A medical physicist’s guide to MRI‐guided focused ultrasound body systems

Payne

Chopra

Ellens³

et al. 2021

Medical Physics

View full text Add to dashboard Cite

Magnetic resonance‐guided focused ultrasound (MRgFUS) is a completely non‐invasive technology that has been approved by FDA to treat several diseases. This report, prepared by the American Association of Physicist in Medicine (AAPM) Task Group 241, provides background on MRgFUS technology with a focus on clinical body MRgFUS systems. The report addresses the issues of interest to the medical physics community, specific to the body MRgFUS system configuration, and provides recommendations on how to successfully implement and maintain a clinical MRgFUS program. The following sections describe the key features of typical MRgFUS systems and clinical workflow and provide key points and best practices for the medical physicist. Commonly used terms, metrics and physics are defined and sources of uncertainty that affect MRgFUS procedures are described. Finally, safety and quality assurance procedures are explained, the recommended role of the medical physicist in MRgFUS procedures is described, and regulatory requirements for planning clinical trials are detailed. Although this report is limited in scope to clinical body MRgFUS systems that are approved or currently undergoing clinical trials in the United States, much of the material presented is also applicable to systems designed for other applications.

show abstract

High-intensity focused ultrasound for prostate cancer

Cited by 42 publications

References 72 publications

Bifidobacterium bifidum-Mediated Specific Delivery of Nanoparticles for Tumor Therapy

Bifidobacterium bifidum-Mediated Specific Delivery of Nanoparticles for Tumor Therapy

High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform

AAPM Task Group 241: A medical physicist’s guide to MRI‐guided focused ultrasound body systems

Contact Info

Product

Resources

About